Dendritic cell tumor injection (dcti) therapy
AssigneeHasumi International Research Foundation
InventorKENICHIRO HASUMI
Life of this patent
Estimating the term…
Abstract
The invention relates to a method of treating tumor cells within a patient wherein immature dendritic cells developed from the patient's monocyte cells and a lymphocyte cultured medium (LCM) adjuvant are introduced into the patient directly into the patient's tumor cells. The immature dendritic cells and LCM adjuvant combine with the antigens in the tumor cells to form a cancer vaccine, thereby immediately treating the tumor cells of the patient. The invention also provides a precursor treatment step of treating the patient with radiation therapy or a chemotherapy regimen.
Claims21
(canceled)
(canceled)
(canceled)
(canceled)
A method of stabilizing or regressing a tumor in a patient comprising the steps of:
- collecting monocyte cells from the patient afflicted with the tumor, said tumor selected from the group consisting of cervical cancer, skin cancer, lung cancer, colon cancer, and liver cancer;
- culturing the monocyte cells with IL-4 and GM-CFS to form immature dendritic cells from the monocyte cells;
- and
- administering a therapeutically effective amount of the immature dendritic cells with a leukocyte cultured medium (LCM) adjuvant to the patient, said LCM adjuvant comprising at least three cytokines selected from the group consisting of eotaxin, FGF, G-CSF, GM-CSF, IFNγ, IP10, IL1β, IL1ra, IL2, IL4, IL5, IL6, IL7, IL8, IL9, IL10, IL12, IL13, IL15, IL17, MCP1, MIP1α, MIP1β, PDGFbb, RANTES, TNFα, and VEGF,
- wherein said immature dendritic cells and LCM adjuvant is administered intratumorally.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of stabilizing or regressing a tumor in a patient comprising the steps of:
- treating a tumor of a patient with a chemotherapy regimen;
- collecting monocyte cells from the patient afflicted with the tumor, said tumor selected from the group consisting of cervical cancer, skin cancer, lung cancer, colon cancer, and liver cancer;
- culturing the monocyte cells with IL-4 and GM-CFS to form immature dendritic cells from the monocyte cells;
- and
- administering a therapeutically effective amount of the immature dendritic cells with a leukocyte cultured medium (LCM) adjuvant to the patient, said LCM adjuvant comprising at least three cytokines selected from the group consisting of eotaxin, FGF, G-CSF, GM-CSF, IFNγ, IP10, IL1β, IL1ra, IL2, IL4, IL5, IL6, IL7, IL8, IL9, IL10, IL12, IL13, IL15, IL17, MCP1, MIP1α, MIP1β, PDGFbb, RANTES, TNFα, and VEGF,
- wherein said immature dendritic cells and said leukocyte cultured medium (LCM) adjuvant is administered intratumorally.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of stabilizing or regressing a tumor in a patient comprising the steps of:
- treating a tumor of a patient with a radiation therapy regimen;
- collecting monocyte cells from the patient afflicted with the tumor, said tumor selected from the group consisting of cervical cancer, skin cancer, lung cancer, colon cancer and liver cancer;
- culturing the monocyte cells with IL-4 and GM-CFS to form immature dendritic cells from the monocyte cells;
- and
- administering a therapeutically effective amount of the immature dendritic cells with a leukocyte cultured medium (LCM) adjuvant into the tumor tissue of the patient, said LCM adjuvant comprising at least three cytokines selected from the group consisting of eotaxin, FGF, G-CSF, GM-CSF, IFNγ, IP10, IL1β, IL1ra, IL2, IL4, IL5, IL6, IL7, IL8, IL9, IL10, IL12, IL13, IL15, IL17, MCP1, MIP1α, MIP1β, PDGFbb, RANTES, TNFα, and VEGF,
- wherein said LCM adjuvant comprises at least six cytokines selected from the group consisting of eotaxin, FGF, G-CSF, GM-CSF, IFNγ, IP10, IL1β, IL1ra, IL2, IL4, IL5, IL6, IL7, IL8, IL9, IL10, IL12, IL13, IL15, IL17, MCP1, MIP1α, MIP1β, PDGFbb, RANTES, TNFα, and VEGF,
- wherein the immature dendritic cells and the LCM adjuvant is administered intratumorally.
(canceled)
(canceled)
A method of stabilizing or regressing a tumor in a patient comprising the steps of:
- collecting monocyte cells from the patient afflicted with the tumor, said tumor selected from the group consisting of cervical cancer, skin cancer, lung cancer, colon cancer, and liver cancer;
- culturing the monocyte cells with IL-4 and GM-CFS to form immature dendritic cells from the monocyte cells;
- combining the immature dendritic cells and a leukocyte cultured medium adjuvant to form a composition, said leukocyte cultured medium adjuvant comprising at least three cytokines selected from the group consisting of eotaxin, FGF, G-CSF, GM-CSF, IFNγ, IP10, IL1ra, IL2, IL4, IL5, IL6, IL7, IL8, IL9, IL10, IL12, IL13, IL15, IL17, MCP1, MIP1α, MIP1β, PDGFbb, RANTES, TNFα, and VEGF;
- and
- administering intratumorally a therapeutically effective amount of the composition to the patient.
Dependencies are inferred from the claim text.